Teva Pharmaceutical Industries Limited provided earnings guidance for the year 2022. For the period, the company expects guidance for operating income, EBITDA, EPS and free cash flow remains unchanged. At current rates, the company still expect foreign exchange fluctuation to have an unfavorable impact on revenue and therefore, believe that consistent with what had communicated in May, at this time, it's also prudent to adjust guidance range for full year revenue from the previous range of $5.4 billion to $16 billion to the new range of $15 billion to $15.6 billion.

This lowers the midpoint of range by $400 million.